1-800-710-4674

For Physicians

  • Phase I Clinical Trial for Patients with Muscle Invasive Bladder Cancer

    David M. Waterhouse, MD, Co-Chair, Department of Clinical Research, OHC, For Physicians 0 comments
    July 22, 2016

    OHC Clinical Trials Photo

    OHC’s Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-State to participate in innovative studies which include targeted and immunotherapies. In order to obtain FDA approval, all drugs (and combinations of drugs) must be rigorously tested in the clinical trial setting. Such new drug development occurs in “Phases.” […]

    Read More
  • Bladder Cancer in Review

    Benjamin T. Herms, M.D., Hematology-Medical Oncology for OHC, For Physicians 0 comments
    July 22, 2016

    iStock-74618039-OHC-Blog-600x400

    Bladder cancer – the fourth most common cancer in the United States among men and ninth among women – arises in the lining of the bladder and is highly treatable. With 50,000 new cases diagnosed each year, a quick review is timely: Risk Factors Smoking is thought to cause about half of all bladder cancers […]

    Read More
  • Phase I Clinical Trials Offer Patients More Benefits Than Ever Before

    David M. Waterhouse, MD, Co-Chair, Department of Clinical Research, OHC, For Physicians 0 comments
    June 7, 2016

    OHC Cancer Doctor Patient Clinical Trial

    The OHC Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-state to participate in innovative studies which include targeted therapies. OHC’s history of successful participation in cutting-edge clinical trials has provided the OHC Research Department with the opportunity to open numerous Phase I clinical trials in the past […]

    Read More
  • OHC Gynecology Oncology Clinical Trial Update

    Cynthia Chua, M.D., OHC Principal Investigator, Gynecology Oncology Clinical Trials, For Physicians 0 comments
    March 3, 2016

    Clinical Trials Update OHC 600x380

    The OHC Department of Clinical Research is offering a clinical trial, GYN41, utilizing Doxil with or without Trabectedin (YONDELIS), a DNA-binding agent that inhibits inducible transcription. This trial is enrolling advanced relapsed patients with Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube cancer. Currently, there are few prospective studies that have examined the third-line treatment of patients […]

    Read More
  • Update on Cervical Cancer Screening Guidelines

    Sarah Wilson, MSN, APRN, OHC Gynecology Oncology Advanced Practice Provider, For Physicians 4 comments
    March 3, 2016

    Cervical-Cancer-Guidelines-OHC

    According to the American Cancer Society’s estimates for cervical cancer in the United States for 2016: About 12,990 new cases of invasive cervical cancer will be diagnosed. About 4,120 women will die from cervical cancer. Historically, cervical cancer was once one of the most common causes of cancer death for American women. But over the […]

    Read More
  • OHC Research Clinical Trial Updates

    OHC, Blogs, For Physicians 0 comments
    December 22, 2015

    Clinical Trial Updates

    OHC is offering two new clinical trials. To view our entire research clinical trial menu, please click here. 1) Lynch Syndrome Trial This is an investigational trial that runs analyses on patients’ blood, saliva, and tumor tissue to determine if they have “Lynch Syndrome.” If it is determined that they do have Lynch Syndrome, The Ohio […]

    Read More
  • Cancer Treatment Advances: A Year In Review – OHC

    Randy Broun, M.D., President, OHC, Blogs, For Physicians, News Releases 0 comments
    December 22, 2015

    Cancer Advances and Breakthroughs in 2015 OHC

    We have seen significant progress in how cancer is treated this last year. Individualized and personalized therapy has revolutionized the treatment plan for many cancer types. Nivolumab, a new immunotherapy drug used to treat advanced non-squamous, non small-cell lung cancer, was approved ahead of schedule by the FDA this year as a result of the […]

    Read More